These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23643389)

  • 1. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.
    Hu X; He Y; Wu L; Hao Y; Wang Z; Zheng W
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5446-5449. PubMed ID: 29138025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
    Hao Y; Zhao S; Wang Z
    Toxicol Pathol; 2014 Jan; 42(1):140-7. PubMed ID: 24178578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
    Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
    Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
    Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
    Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
    Zhao L; Vogt PK
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
    Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
    PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Lipid Alterations by Oncogenic
    Jung JH; Yang DQ; Song H; Wang X; Wu X; Kim KP; Pandey A; Byeon SK
    OMICS; 2023 Jul; 27(7):327-335. PubMed ID: 37463468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
    Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
    Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.